This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.
(-)-Epicatechin and the colonic metabolite 2,3-dihydroxybenzoic acid protect against high glucose and lipopolysaccharide-induced inflammation in renal proximal tubular cells through NOX-4/p38 signalling

David Álvarez Cilleros¹, María Elvira López-Oliva², María Ángeles Martín¹,³ and Sonia Ramos¹,*

¹Department of Metabolism and Nutrition
Institute of Food Science and Technology and Nutrition (ICTAN)
Consejo Superior de Investigaciones Científicas (CSIC)
José Antonio Novais 10
Ciudad Universitaria, 28040, Madrid
Spain
Phone: +34.91.544.56.07
Fax: +34.91.549.36.27

²Sección Departamental de Fisiología. Facultad de Farmacia, Universidad Complutense de Madrid (UCM), Spain.

³Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), ISCIII, Spain.

* Corresponding author: e-mail: s.ramos@ictan.csic.es
Abstract

Chronic hyperglycaemia and inflammation are present in diabetes, and both processes have been related to the pathogenesis of the diabetic kidney disease. Epicatechin (EC) and main colonic phenolic acids derived from flavonoid intake, such as 2,3-dihydroxybenzoic acid (DHBA), 3,4-dihydroxyphenylacetic acid (DHPAA) and 3-hydroxyphenylpropionic acid (HPPA) have been suggested to exert beneficial effects in diabetes. This study was aimed at investigating whether the mentioned compounds could prevent inflammation in renal proximal tubular NRK-52E cells induced by high glucose and lipopolysaccharide (LPS). Pre-treatment of cells with EC and DHBA (5 µM) reverted the enhanced levels of pro-inflammatory cytokines, such as tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6) and monocyte chemoattractant protein 1 (MCP-1) activated by high glucose and LPS. Additionally, EC and DHBA pre-incubation reduced the increased values of adhesion molecules namely intercellular cell adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1), as well as those of mitogen-activated protein kinases (MAPKs) [extracellular signal-regulated kinase (ERK), -c-jun N-terminal kinase (JNK) and -p38 protein kinase (p38)] provoked by the high glucose and LPS challenge. Thus, in EC and DHBA pre-treated cells ICAM-1, p-ERK and p-JNK were returned to control values, and VCAM-1 and p-p38 levels were diminished in ~20 and 25%, respectively when compared to high glucose plus LPS stimulated cells. Likewise, EC and DHBA pre-treatment protected against high glucose plus LPS-triggered oxidative stress by preventing increased ROS and NADPH-oxidase-4 (NOX-4) levels (~25 and 45% reduction, respectively). By using specific inhibitors of p38 and NOX-4, the participation of both proteins in EC- and DHBA-mediated protection against inflammation and associated oxidative stress was shown. Taken together, EC and DHBA exert beneficial effects in renal proximal tubular cells as contribute to prevent the
inflammatory-induced milieu and the accompanying redox imbalance, playing NOX-4/p38 a crucial role.
1. Introduction

Diabetes kidney disease (DKD) is a major complication of diabetes that affects one third of the diabetic patients, and constitutes one of their main causes of death in this disease.\(^1\) During diabetes, renal tubules are vulnerable to various stimuli, such as high glucose microenvironment and inflammation, among others. Thus, in DKD chronic hyperglycaemia is associated to the early renal tubular damage and contributes to the progression of the renal dysfunction.\(^2\) Additionally, the low-grade inflammation found in diabetes, both systemic and localized in tissues, has been directly associated to the pathogenesis of diabetic complications, including DKD.\(^3\) Accordingly, enhanced levels of glucose, as well as lipopolysaccharide (LPS) and pro-inflammatory factors have been reported in diabetic patients with nephropathy.\(^3,4\)

At molecular level, during DKD multiple signalling pathways are altered and directly contribute to the progression of the disease, being crucial the role of NADPH-oxidase-4 (NOX-4) and the three groups of mitogen-activated protein kinases (MAPKs): c-jun N-terminal kinase (JNK), p38 protein kinase (p38) and extracellular signal-regulated kinase (ERK), which are also closely linked to the underlying oxidative stress.\(^5\) Importantly, this complex dysregulation of the signalling network during DKD also leads to enhanced levels of different inflammatory mediators, such as tumour necrosis factor-\(\alpha\) (TNF-\(\alpha\)), intercellular cell adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), monocyte chemoattractant protein (MCP-1) and interleukin (IL)-6.\(^5\) In fact, recently DKD has also started to be considered as an inflammatory disease;\(^3\) therefore, anti-inflammatory agents might be beneficial for the amelioration of this disease. In this regard, it is becoming clear that it is important to counteract the diabetic pathophysiology through different vias by using multi-target agents.
Natural compounds constitute a valuable source of chemopreventive agents concerning chronic diseases.\textsuperscript{6-9} Thus, natural components are considered good candidates against chronic diseases, such as diabetes, and also DKD, for their broad range of biological properties by modulating multiple targets and lack of toxicity.\textsuperscript{7-9} Among these natural compounds, flavanols, such as (-)-epicatechin (EC), are abundant in cocoa, grapes, tea, and many other fruits and vegetables,\textsuperscript{6,7,10} and are important candidates with demonstrated health-promoting effects, including antidiabetic properties.\textsuperscript{7-10} It has become clear that health effects of phenolic compounds depend on their bioavailability.\textsuperscript{7,11-13} Thus, when evaluating the impact of polyphenols on health the contribution of both food polyphenols and metabolites, including low molecular weight phenolic acids derived from the colonic intestinal microbiota should be taken into account.\textsuperscript{7,11-13} It has been reported that these microbial metabolites constitute a great rate of the amount ingested and circulate in the body prior to their urinary excretion. In this line, mono- and di-hydroxylated phenylpropionic and phenylacetic acids are main colonic phenolic acids derived from flavanol-rich food intake (grapes, apples, pears, legumes, cocoa, wine cider, beer)\textsuperscript{11}, and after being absorbed could be detected in serum before their elimination via urine\textsuperscript{11,12}; in addition, part of these metabolites could be metabolized by hepatic phase II enzymes (conjugated derivatives)\textsuperscript{11,12}. Thus, concentrations in the range of micromolar for these phenolic acids in human plasma and urine after the intake of cocoa products have been reported,\textsuperscript{14,15} contributing to the health-promoting effects.\textsuperscript{11,12} Indeed, similarly to the monomer EC colonic phenolic acids seem to exhibit anti-diabetic effects by multiple mechanisms.\textsuperscript{7} EC and some colonic polyphenolic metabolites are able to prevent key features of diabetic complications related to insulin sensitivity and oxidative stress,\textsuperscript{12,16-18} and avert inflammation in insulin-sensitive tissues.\textsuperscript{6,9,12,19} Nevertheless, the role of the inflammatory cytokines in the injury during DKD is largely unknown, and in line with...
this, it also remains unclear whether EC and the colonic phenolic metabolites derived
from flavanol intake exert a protective effect on renal tubular cells against the
inflammation during diabetes.

Therefore, the goal of this work is to analyse the effects of EC and the microbial-derived
flavonoid metabolites 2,3-dihydroxybenzoic acid (DHBA), 3,4-dihydroxyphenylacetic
acid (DHPAA), and 3-hydroxyphenylpropionic acid (HPPA) on main inflammatory
mediators and on key modulatory mechanisms related to the inflammatory process in
renal proximal tubular NRK-52E cells exposed to a high glucose plus LPS challenge.
2. Materials and methods

2.1. Materials and chemicals

(-)-EC (>95% of purity), DHBA (>99% of purity), DHPAA (>98% of purity), HPPA (>98% of purity), diphenyleneiodonium (DPI), SB203580 were purchased from Sigma Chemicals (Madrid, Spain). Lipopolysaccharide (LPS) from *E. coli* 0111:B4 strain was from Invivogen (Nucliber, Madrid, Spain). TNF-α and IL-6 kits were acquired from R&D systems (Abingdon, United Kingdom) and Invitrogen (Thermofisher, Madrid, Spain), respectively. Anti-ERK1/2 and antiphospho-ERK1/2 recognizing phosphorylated Thr202/Thr204 of ERK1/2, anti-JNK1/2 and antiphospho-JNK1/2 recognizing phosphorylated Thr183/Tyr185 of JNK1/2, antiphospho-Thr180/Tyr182-p38, and anti-β-actin were obtained from Cell Signalling Technology (Izasa, Madrid, Spain). Anti-TNF-α (sc-52746), anti-IL-6 (sc-57315), anti-VCAM-1 (sc-13160), anti-ICAM-1 (sc-107), anti-MCP-1 (sc-52701), p38α (sc-535), and anti-NOX-4 (sc-30141) were purchased from Santa Cruz Biotechnology (Qimigen, Madrid, Spain). Materials and chemicals for electrophoresis were from BioRad (BioRad Laboratories S.A., Madrid, Spain). Cell culture dishes, glutamine and cell culture medium were from Falcon (Cajal, Madrid, Spain) and Lonza (Madrid, Spain), respectively.

2.2. Cell culture and treatments

Rat NRK-52E cells (kindly provided by Prof. Dr. Patricio Aller, Centro de Investigaciones Biológicas, CSIC, Madrid, Spain) were grown in DMEM medium containing 5.5 mM D-glucose, 2 mM glutamine, supplemented with 10% foetal bovine serum (FBS). Cells were maintained at 37°C in a humidified atmosphere of 5% CO₂. Subsequently, the experimental treatment was carried out with various concentrations of
LPS in the presence of a high concentration of glucose (30 mM), as previously reported in serum-free media for 24 h. In the experiments with the natural compounds, cells were treated with different concentrations of EC, DHBA, DHPAA or HPPA (1-10 μM) diluted in serum-free culture medium with 5.5 mM D-glucose and 2 mM glutamine during 24 h (Fig 1S).

To evaluate the protective effect of EC, DHBA, DHPAA and HPPA against LPS plus high glucose challenge, 1-10 μM of each compound were added to the cells for 2 h. Then, cells were submitted to a challenge with LPS (1 μg/mL) plus glucose (30 mM) for 22 h (Fig 1S). In the experiments with the inhibitors, cells were pre-incubated with 20 μM SB203580 (p38 inhibitor) or 10 μM DPI (NADH oxidase inhibitor) for 1 h prior to EC or DHBA treatment for 2 h followed by the LPS plus high glucose (HG+LPS) challenge (Fig 1S).

2.3. Cell viability assay

Cell viability was determined by using the crystal violet assay. NRK-52E cells were seeded at low density (10^4 cells per well) in 96-well plates. After the treatment, cells were incubated with crystal violet (0.2% in ethanol) for 20 min. Plates were rinsed with water, allowed to dry, and 1% sodium dodecylsulfate was added. The absorbance was measured using a microplate reader at 570 nm.

2.4. TNF-α and IL-6 analysis

Cells were cultured in 24-well plates (2×10^5 cells per well) and after the different treatments culture supernatants were collected and concentrations of TNF-α and IL-6 measured by ELISA following protocols supplied by the manufacturer and normalized to
cell protein concentration. Protein was measured by the Bradford reagent (Bio-Rad, Madrid, Spain).

2.5. Reactive oxygen species (ROS) generation analyses

Intracellular ROS were quantified by the DCFH assay as described elsewhere. Briefly, cells were cultured in 24-well plates (2×10^5 cells per well) and incubated with the different treatments. Then, 5 μM DCFH probe was added to the wells and kept for 30 min at 37°C. After being oxidized by intracellular oxidants, DCFH becomes dichlorofluorescein (DCF) and emits fluorescence. Fluorescence was measured in a microplate reader (Bio-Tek, Winooski, VT) at 485 nm/530 nm (excitation/emission wavelengths, respectively).

2.7. Cell lysates preparation

Cells were lysed at 4°C in a buffer containing 25 mM HEPES (pH 7.5), 0.3 M NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.1% Triton X-100, 200 mM β-glycerolphosphate, 0.1 mM Na₃VO₄, 2 μg/mL leupeptin and 1 mM phenylmethylsulfonyl fluoride. Supernatants were collected, assayed for protein concentration by the Bradford reagent (Bio-Rad, Madrid, Spain), aliquoted and stored at -80°C until used for Western blot analyses.

2.8. Western blot analysis

Equal amounts of proteins were separated by SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride filters (Merck, Madrid, Spain). Membranes were probed with the corresponding primary antibody (all antibodies were used at dilution 1:1000, except for IL-6, TNF-α and NOX-4 that were employed at 1:500) followed by
incubation with peroxide-conjugated anti-rabbit (GE Healthcare, Madrid, Spain) or anti-mouse (Sigma, Madrid, Spain) immunoglobulin (1:5000 and 1:3000, respectively). Blots were developed with the ECL system (GE Healthcare, Madrid, Spain). Normalization of Western blot was ensured by β-actin and bands were quantified using a scanner and accompanying software.

2.9. Statistics

Prior to statistical analysis, data were tested for homogeneity of variances by the test of Levene; for multiple comparisons, one-way ANOVA was followed by the Bonferroni test when variances were homogeneous or by the Tamhane test when variances were not homogeneous. $P<0.05$ was considered significant. A SPSS version 23.0 program has been used.
3. Results

3.1. Effects of LPS plus high glucose challenge on cell viability, ROS generation and levels of pro-inflammatory cytokines.

Hyperglycaemia and inflammation are present in diabetes, being also persistent oxidative stress a key player in the development and progression of this disease. To establish a model in renal tubules, cells were exposed to a commonly used high concentration of glucose (30 mM) and rising doses of LPS for 24 h; then, cell viability, ROS generation and main pro-inflammatory cytokines were evaluated.

Treatment of NRK-52E cells for 24 h with all LPS concentrations combined with high glucose (30 mM, HG) did not affect cell viability, indicating that the concentrations selected for the study did not damage cell integrity during the period of incubation (Table 1). Moreover, 30 mM glucose in combination with 1 µg/mL LPS increased IL-6 levels in the culture medium, whereas ROS generation and TNF-α values were already increased with HG alone and with HG plus 0.5 µg/mL LPS, respectively (Table 1). Similarly, as shown in Fig 1 all tested concentrations of LPS in combination with 30 mM glucose enhanced the expression levels of TNF-α in the cells, and 0.5 µg/mL LPS+HG already displayed an increased IL-6 cellular content. In addition, MCP-1 expression levels were also augmented in HG plus 1 µg/mL LPS-stimulated NRK-52E cells (Fig 1). All these data suggest that a high dose of glucose (30 mM) in combination with LPS (≥ 1 µg/mL) are able to induce inflammation and accompanying oxidative stress in NRK-52E cells to simulate a situation that resembles diabetes with a low-grade of inflammation in renal proximal tubular cells.

Since 1 µg/mL LPS+HG was the lowest combination of concentrations that clearly altered levels of the pro-inflammatory cytokines tested (TNF-α, IL-6 and MCP-1) and the redox status in NRK-52E cells, this was the experimental condition selected for further
studies. Indeed, selected concentrations of LPS and glucose have been widely employed alone or in combination in inflammatory models of renal cells to resemble a diabetic situation.\textsuperscript{16,20,21} Interestingly, similar circulating levels of glucose and LPS to the concentrations selected in this work have been reported in diabetic mice.\textsuperscript{23}

3.2. Direct and protective effects of EC and colonic phenolic metabolites on ROS generation and levels of pro-inflammatory cytokines.

To discard a potential pro-inflammatory effect of EC and microbial phenolic metabolites, NRK-52E cells were treated with doses of EC, DHBA, DHPAA and HPPA (1-10 μM) during 24 h and levels of TNF-α and IL-6 were evaluated. The rationale for selecting these concentrations of phenolic compounds is because these doses are considered to be within the range recommended for \textit{in vitro} studies, and they can be found in biological fluids\textsuperscript{11}; in addition, beneficial effects have been reported with similar concentrations of phenolic compounds in previous studies with cellular models resembling diabetes, including renal cells.\textsuperscript{6,7,16,17,24}

As shown in Table 2, none of the tested concentrations of EC or phenolic metabolites increased levels of TNF-α or IL-6 in the culture medium, indicating no-induced cellular inflammation. In agreement with these results, we have already reported that in NRK-52E a 24 h-treatment with the same concentrations of EC and phenolic metabolites used in the present work did not evoke damaging changes or enhanced ROS generation.\textsuperscript{16,25} These results ensure that NRK-52E cells treated with EC or microbial phenolic metabolites (1-10 μM) are functional and in competent conditions to face a stressful challenge.

Next, to evaluate the potential protective effect of EC and the colonic phenolic metabolites, cells were pre-treated for 2 h with EC, DHBA, DHPAA or HPPA (1-10 μM)
prior to 22 h-HG+LPS challenge; then, ROS generation, as well as TNF-α and IL-6 levels were assayed. Pre-treatment of NRK-52E cells with DHPPA or HPPA did not prevent the enhancement in ROS generation or TNF-α and IL-6 culture media values evoked by the HG+LPS challenge. Interestingly, 5-10 µM EC and DHBA pre-incubation completely or partly reversed to pre-stress levels the HG+LPS-induced ROS production and the values of the mentioned pro-inflammatory cytokines, respectively (Table 3). Therefore, the lowest concentration for both compounds that showed a protective effect against ROS generation and secreted levels of TNF-α and IL-6 was selected for further studies, that is 5 µM EC and DHBA. In line with this and in agreement with the results obtained in the medium, reduced cellular expression levels of pro-inflammatory cytokines (TNF-α, IL-6 and MCP-1) assayed by Western blot were detected in NRK-52E cells pre-incubated with 5 µM EC or DHBA in comparison to HG+LPS-stimulated cells (Fig 2); as mentioned above, cells incubated with EC or DHBA alone presented similar values of TNF-α, IL-6 and MCP-1 to those of untreated cells.

3.3. Effects of EC and DHBA on VCAM-1 and ICAM-1 adhesion protein levels in high glucose plus LPS-exposed renal tubular cells.

Altered levels of adhesion proteins, such as VCAM-1 and ICAM-1, have been associated to different pathologies, such as the sub-chronic inflammation present in diabetes. To investigate whether the exposure of renal tubular cells to EC or DHBA can prevent the increase in VCAM-1 and ICAM-1 induced by HG+LPS incubation, NRK-52E cells were pre-treated with 5 µM of EC or DHBA for 2 h and later exposed to the mentioned challenge during 22 h. Treatment of NRK-52E cells with HG+LPS increased levels of VCAM-1 and ICAM-1, whereas EC or DHBA alone did not modify the expression of both adhesion proteins.
when compared to untreated cells (Fig 3). Likewise, pre-incubation with EC or DHBA prevented the enhancement in ICAM-1 values, showing comparable levels to those of cells treated with EC or DHBA alone (Fig 3B); however, VCAM-1 values were partially restored to controls by pre-treating the cells with both natural compounds (Fig 3A).

3.4. Effects of EC and DHBA on MAPKs levels in high glucose plus LPS-exposed renal proximal tubular cells.

MAPKs are induced by high doses of glucose and inflammatory conditions (LPS) and regulated by oxidative stress. Then, cells were pre-treated for 2 h with 5 µM EC or 5 µM DHBA prior to 22 h-HG+LPS incubation, and phosphorylated and total levels of MAPKs were evaluated.

As shown in Fig 4, HG+LPS challenge increased the phosphorylated levels of all three MAPKs (p-ERK, p-JNK and p-p38), whereas EC and DHBA alone did not modify any phosphorylated levels of the mentioned proteins in comparison to control cells. In addition, pre-treatment with EC or DHBA returned to control values (untreated cells) the enhanced phosphorylated values of ERK and JNK induced by HG+LPS, whereas p-p38 levels were partially repressed when compared to untreated cells (Fig 4). Total levels of ERK, JNK and p38 were not modified by any treatment.

3.5. p38 regulates EC- and DHBA-induced changes on pro-inflammatory cytokines, ROS and NOX-4 protein levels in high glucose plus LPS-exposed renal tubular cells.

Diabetes, inflammation and oxidative stress are linked, being MAPKs a key family of proteins involved in all these processes. To further determine the potential role of p38-MAPK in the modulation of the pro-inflammatory process induced in HG+LPS-stimulated cells, the effect of a p38 selective inhibitor was assayed. Accordingly, cells
were pre-incubated with 20 μM SB (p38 inhibitor) for 1 h prior to 2 h-treatment with EC or DHBA followed by HG+LPS incubation (22 h). Fig 2S shows that in EC- and DHBA-pre-treated cells SB reduced p-p38 levels induced by HG+LPS to values that were lower than those of controls. Additionally, as shown in Fig 5, in cells pre-treated with EC or DHBA, HG+LPS-induced TNF-α, IL-6 and MCP-1 levels were highly blocked when SB was present, showing even lower values than those of control cells. In addition, the production of ROS and levels of NOX-4, which is considered a main source of ROS in the kidney, induced by HG+LPS were completely blocked in EC- and DHBA-incubated cells previously treated with the pharmacological inhibitor of p38 (Fig 6). Altogether, these results suggest that the inhibitory effect exerted by EC and DHBA on p38 phosphorylation could be involved in the repression of cytokine production and induction of oxidative stress (ROS and NOX-4 levels) in NRK-52E cells.

3.6. NOX-4 regulates EC- and DHBA-induced changes on pro-inflammatory cytokines, ROS and p38 protein levels in high glucose plus LPS-exposed renal proximal tubular cells.

As mentioned above NOX-4 is a main source of ROS in the kidney, and oxidative stress is related to the low-grade of inflammation in diabetes. Then, the effect of NOX-4 inhibition, induced with DPI, on cells pre-treated with EC or DHBA (5 μM) under HG+LPS conditions was analysed in terms of ROS production, p38, TNF-α, IL-6 and MCP-1 levels. Fig 3S shows in EC- and DHBA-pre-incubated cells with DPI a diminution in NOX-4 levels induced by HG+LPS, displaying values lower than those of control cells. Furthermore, as shown above, EC and DHBA pre-treatment totally prevented the increase in ROS generation observed in HG+LPS-stimulated cells, achieving values similar to those of control cells, whereas p-p38 levels displayed intermediate values to those of
untreated and phenolic-incubated cells (Fig 7). Similarly, under HG+LPS conditions, the incubation with DPI (blockage of NOX-4) in cells pre-treated with EC or DHBA suppressed the enhancement in ROS production and p-p38 values evoked by the HG+LPS challenge, and showed levels comparable to those of EC- or un-treated cells (Fig 7). Additionally, in HG+LPS-stimulated cells previously incubated with DPI and EC or DHBA the increased values of TNF-α, IL-6 and MCP-1 were completely averted (Fig 8). All these suggest that the inhibition of NOX-4 seems to act in a similar manner of that of EC and DHBA to modulate the cellular redox status and to improve the anti-inflammatory protection induced by EC and DHBA.
4. Discussion

DKD is a major diabetic complication that contributes to exacerbate the severity and mortality of diabetes. At present, the inflammatory process has been added to the classical hemodynamic and metabolic alterations as a main cause of renal damage in DKD. Interestingly, the role of inflammatory cytokines in the renal injury during DKD remains still unknown.

Different studies have reported that cocoa and EC possess antioxidant and anti-inflammatory properties. Additionally, it has been shown that cocoa and EC can prevent or delay the injury associated to diabetes by reducing the glycaemia and modulating the oxidative stress. After consumption of flavanols-rich foods mono- and di-hydroxylated phenylpropionic, phenylacetic and hydroxybenzoic acids and conjugated forms are the most abundant metabolites in urine and plasma. However, it has been proved that conjugation could be a reversible process in vivo, and as a result pure compounds could be accumulated in tissues. Accordingly, in the present work the potential beneficial effect of EC and most abundant phenolic acids in plasma and urine after flavanol intake (DHBA, DHPAA and HPPA) on renal cells in terms of inflammation was investigated. For the first time it is demonstrated that EC and DHBA attenuate the pro-inflammatory conditions induced by a high dose of glucose combined with LPS through the prevention of the increase in main pro-inflammatory mediators (TNF-α, IL-6 and MCP-1), adhesion molecules (VCAM-1 and ICAM-1), as well as MAPKs (ERK, JNK and p38) and the diminution of ROS generation. Furthermore, it is shown that EC and DHBA protect NRK-52E cells against the high glucose plus LPS challenge by modulating key pro-inflammatory cytokines via p38-MAPK and NOX-4.

During diabetes the low-grade chronic inflammation has been related to hyperlipidaemia and hemodynamic disarrangements, being the activation of the renin angiotensin...
aldosterone system, which interacts with nitric oxide and ROS, prominent feature.

Importantly, also contribute to the pro-inflammatory milieu the increased glycaemia and endotoxemia, resulting this latter mainly from LPS of Gram negative bacteria;\textsuperscript{28} in turn, inflammation has also been associated to the pathogenesis of diabetes complications, including DKD.\textsuperscript{3} Thus, to resemble this situation of low-grade chronic inflammation during diabetes renal tubular cells were incubated with a high concentration of glucose (30 mM) plus LPS (1 µg/mL).\textsuperscript{20} In these experimental conditions, alterations in the inflammatory response and redox balance without modifying cell viability have also been reported in in vitro and animal models, as well as in diabetic patients.\textsuperscript{24,29,30} On the contrary, pre-incubation of HG plus LPS-stimulated cells with EC or DHBA prevented the enhanced levels of ROS, TNF-\textit{\alpha} and IL-6. In this regard, it should be considered that increased levels of pro-inflammatory cytokines have also been related to an augmented oxidative stress and promotion of the renal damage associated to DKD.\textsuperscript{3,30,31} Therefore, prevention of the enhancement in pro-inflammatory cytokines and maintenance of the redox balance by different natural compounds have been connected to an amelioration of kidney damage.\textsuperscript{16,24,29,31-34} Additionally, enhanced IL-6 renal expression has been related to mesangial proliferation and tubular atrophy in several models of renal disease, as well as to the progress of DKD;\textsuperscript{3,35} indeed, decreased IL-6 levels, which might result from treatments with natural phenolic compounds, have been associated to an improvement of kidney functionality in DKD.\textsuperscript{24,31,32}

MCP-1 is a chemotactic factor induced by oxidative stress and high glucose concentrations,\textsuperscript{35} that activates monocytes and macrophages, and promotes their migration to lesions, playing a relevant role in the development of DKD.\textsuperscript{3,4} In the present work, MCP-1 levels were increased in HG+LPS-treated cells, but this was highly prevented when cells were previously incubated with EC or DHBA. Different authors
have shown augmented MCP-1 levels in renal diabetic in vivo and in vitro models, as well as in diabetic patients.\textsuperscript{4,24,36,37} However, this enhancement in MCP-1 values, as well as other pro-inflammatory mediators (IL-6 and TNF-α), was avoided by the administration of different natural phenolic compounds, such as a new chalcone, caffeic acid, ellagic acid, acai catechin-rich extract, genistein and anthocyanins, promoting a relief of the renal damaging situation.\textsuperscript{24,29,31,36,37}

Increased expression levels of TNF-α, ICAM-1 and VCAM-1 might be stimulated by hyperglycaemia and/or LPS, and lead to an inflammatory situation in DKD.\textsuperscript{38} ICAM-1 expression can be locally induced by hyperglycaemia, oxidative stress, hyperlipidaemia, hyperinsulinaemia and TNF-α, among other factors.\textsuperscript{4} Moreover, different experimental models of DKD have shown that ICAM-1 expression is directly associated to the severity of the renal damage, and plays a main role in the promotion of macrophage infiltration and DKD.\textsuperscript{3} Thus, reduced levels of ICAM-1 have been connected to an alleviation of the inflammation in the diabetic nephropathy and correlated to TNF-α values,\textsuperscript{4} as shown in EC- and DHBA-treated cells. Consistent with this, it has been reported that genistein, a new chalcone and anthocyanins decrease the production of this inflammatory marker in in vitro and in vivo models of DKD.\textsuperscript{24,36,37} In addition, several clinical studies have demonstrated an augmented production of VCAM-1 in renal tubules during DKD.\textsuperscript{39} Accordingly, increased expression levels were observed in HG plus LPS-stimulated cells, but this was highly prevented when cells were previously treated with EC or DHBA. In line with this, a new chalcone and epigallocatechin-3-gallate (EGCG) have shown to ameliorate the expression levels of inflammatory markers, such as VCAM-1 and ICAM-1 in NRK-52E cells and diabetic mice, respectively.\textsuperscript{24,40} Interestingly, these adhesion molecules are also induced by ROS,\textsuperscript{4,40} and in agreement with the present results a parallelism between ROS and adhesion molecules levels (ICAM-1 and VCAM-1) has
Correspondingly, EGCG improved the redox status by diminishing oxidative stress, leading to reduced levels of main adhesion molecules (VCAM-1 and ICAM-1) and ameliorated inflammatory renal damage in diabetic mice.\textsuperscript{40}

Marked activation of all three MAPKs occurs in DKD, and this feature has been associated to inflammation and the accompanying oxidative stress,\textsuperscript{5,24} as shown. Additionally, pre-treatment with EC or DHBA prevented the activation of the three MAPKs in renal tubular cells treated with the high concentration of glucose plus LPS. Similarly, procyanidin B2 decreased the phosphorylation of p38 in renal proximal tubular cells, showing a protective effect.\textsuperscript{41} Consistent with this, other phenolic compounds such as genistein, a novel chalcone and oligonol have demonstrated anti-inflammatory and anti-diabetic effects through the down-regulation of MAPKs \textit{in vitro} and \textit{in vivo}.\textsuperscript{24,32,36}

MAPK-p38 seems to be the MAPK pathway most closely associated with LPS-induced upregulation of inflammatory mediators, and it is also connected to oxidative stress.\textsuperscript{5,42} Therefore, inhibition of p38 would enable to understand better the cross-talk between p38 and the modulation of the cellular inflammatory and redox statuses. In our study, the blockage of p38 reinforced the protective effects exerted by EC and DHBA on high glucose plus LPS-stimulated cells, as diminished values of pro-inflammatory mediators (TNF-\textit{\alpha}, IL-6 and MCP-1), ROS generation and NOX-4 levels were observed. These features suggested that p38 directly or indirectly regulates key proteins to modulate both inflammatory and redox cellular statuses. To the best of our knowledge, the inhibition of p38 induced by flavanols or their metabolites on the previously mentioned parameters in renal tubular cells has not been previously studied. However, it has been demonstrated that inhibitors of p38 (FR167653 and SB203580) reduce the expression of inflammatory cytokines (IL-1\textit{\beta} and TNF-\textit{\alpha}) in the kidney of hypertensive rats, as well as in the hypothalamus and cerebrospinal fluid in a model of inflammation induced by LPS in
Additionally, it could be mentioned that these p38 chemical inhibitors improved the redox status of renal cells, showing similar effects to those of the antioxidant N-acetylcysteine (NAC), such as decreased ROS generation and NOX levels.

NOX-4 contributes to the initiation and development of renal injury in DKD, and its inhibition has been associated to an alleviation of the tubular-induced damage. In agreement, the present results demonstrate for the first time that EC and DHBA prevent HG+LPS-induced NOX-4 expression and contribute to improve both cellular redox and pro-inflammatory statuses. This fact is supported by our findings as inhibition of NOX-4 enhances the protection induced by EC and DHBA in HG+LPS-stimulated cells, showing p-p38 and pro-inflammatory mediators’ levels, as well as ROS generation similar to untreated cells. In agreement, we have demonstrated that the modulation of the redox balance and NOX-4 levels by EC and DHPAA protect NRK-52E cells under high glucose conditions. Similarly, previous studies performed with an acai extract, a flavanol-enriched cocoa, NAC and DPI have proved renoprotective effects by reducing ROS generation and NOX-4 expression values. Moreover, in renal proximal tubular cells inhibition of NOX by DPI reduced p-p38 and MCP-1 levels, being ROS involved in those modulatory effects. All these suggest that EC and DHBA might have a key role to inhibit NOX-4 and to prevent the damage in high glucose plus LPS-stimulated renal tubular cells.

Altogether it could be highlighted that in the present work it is demonstrated the anti-inflammatory activity of EC and DHBA in renal tubular cells. This effect has already been reported for other phenolic compounds (downregulation of main cytokine levels) also in the kidney, but the contribution of these inflammatory cytokines to the renal injury still remains largely unclear. Moreover, this is the first time that a new regulatory
mechanism, in which p38 and NOX-4 play a main role, is proposed for phenolic compounds (EC and DHBA), proving their anti-inflammatory renoprotective. Interestingly, in the present work it is demonstrated that EC and DHBA exert a protective activity against HG+LPS stimuli in NRK-52E cells, whereas DHPAA and HPPA do not show any anti-inflammatory effect. This different outcome could be related to a structure-activity relationship, but this aspect deserves further investigations. In addition, it should be mentioned that after a polyphenol-rich food intake all these phenolic compounds will be present in biological fluids, which might lead to opposite, additive and/or synergistic effects. In this regard, beneficial effects have been reported by using simple and complex mixtures of structurally similar flavonoids and/or metabolites in different cellular models\(^{12,17,49}\); indeed, by performing these approaches insights into structure-activity relationships and differential effects on the activities will be provided.

Conclusions

In summary, EC and the flavanol colonic metabolite DHBA avert the inflammation, as under high glucose plus LPS conditions both compounds prevent the enhancement in the inflammatory cytokines (TNF-\(\alpha\), IL-6 and MCP-1), adhesion molecules (ICAM-1 and VCAM-1), and MAPKs values, and contribute to the balance of the cellular redox status by avoiding the increase in ROS generation and NOX-4 levels (Fig 9). In addition, a new mechanism has been demonstrated by which EC and DHBA avoid the inflammatory milieu in NRK-52E cells, playing the NOX-4/p38 signalling a main role (Fig 9). Altogether, this study provides new evidences on the renoprotective effects of the flavanol EC and the colonic metabolite DHBA under a high glucose plus LPS condition.
Acknowledgements

This work was supported by the grants AGL2015-67087 and RTI2018-095059-B-I00 (MINECO/FEDER, UE) from the Spanish Ministry of Science and Innovation (MINECO). D. Álvarez-Cilleros is a FPI fellow from the predoctoral program of MINECO (BES-2016-076721).

Conflict of interest statement

The authors have declared no conflict of interest.
5. References


Legends to figures

Fig 1. Dose-dependent effect of LPS in the presence of high glucose (30 mM) on TNF-α and IL-6 levels in NRK-52E cells after 24 h of treatment. (A) Bands of representative experiments. Percentage data of (B) TNF-α, (C) IL-6 and (D) MCP-1 relative to the control condition (means ± SD, n=5-8). Equal loading of Western blots was ensured by β-actin. Means without a common letter differ significantly (P<0.05).

Fig 2. Protective effect of EC and DHBA on enhanced levels of TNF-α, IL-6 and MCP-1 induced by the HG+LPS challenge in NRK-52E cells. Cells incubated with 5 μM EC or 5 μM DHBA for 2 h were exposed to 30 mM glucose (HG) plus 1 μg/mL LPS for additional 22 h. (A) Bands of representative experiments. Densitometric quantification of (B) TNF-α, (C) IL-6, and (D) MCP-1. Values were expressed as a percentage relative to the untreated control condition and are means ± SD, n=7-10. Equal loading of Western blots was ensured by β-actin. Means without a common letter differ significantly (P<0.05).

Fig 3. Protective effect of EC and DHBA on increased VCAM-1 and ICAM-1 levels evoked by the HG+LPS challenge in NRK-52E cells. Cells incubated with 5 μM EC or 5 μM DHBA for 2 h were exposed to 30 mM glucose (HG) plus 1 μg/mL LPS for additional 22 h. (A) Bands of representative experiments. Densitometric quantification of (B) VCAM-1 and (C) ICAM-1 levels. Data were expressed as a percentage relative to the control condition (means ± SD, n=6-9). Equal loading of Western blots was ensured by β-actin. Means without a common letter differ significantly (P<0.05).

Fig 4. Effect of EC and DHBA on levels of phosphorylated and total ERK, JNK and p38 in NRK-52E cells. Cells incubated with 5 μM EC or 5 μM DHBA for 2 h were exposed to 30 mM glucose (HG) plus 1 μg/mL LPS for additional 22 h. (A) Bands of representative experiments. Percentage data of
(B) p-ERK/ERK, (C) p-JNK/JNK and (D) p-p38/p38 ratios relative to controls. Values are expressed as a percentage relative to the control condition and are means ± SD, n=6-8. Equal loading of Western blots was ensured by β-actin. Means without a common letter differ significantly (P<0.05).

**Fig 5.** Effect of EC and DHBA and the selective inhibitor SB (SB203580) on levels of TNF-α, IL-6 and MCP-1. NRK-52E cells were incubated in the presence or absence of 20 µM SB for 1 h and later with 5 µM EC or 5 µM DHBA for 2 h followed by the HG+LPS challenge (22 h). (A) Bands of representative experiments. Percentage data of (B) TNF-α, (C) IL-6, and (D) MCP-1 relative to the control condition (means ± SD, n=7-9). Equal loading of Western blots was ensured by β-actin. Means without a common letter differ significantly (P<0.05).

**Fig 6.** Effect of EC and DHBA and the selective inhibitor SB (SB203580) on ROS generation and NOX-4. NRK-52E cells were incubated in the presence or absence of 20 µM SB for 1 h and later with 5 µM EC or 5 µM DHBA for 2 h followed by the HG+LPS challenge (22 h). (A) ROS production was expressed as percent of control are means ± SD of 9-12 different samples per condition. (B) Bands of representative experiments. (C) Percentage data of NOX-4 values relative to the control condition (means ± SD, n=6-8). Equal loading of Western blots was ensured by β-actin. Means without a common letter differ significantly (P<0.05).

**Fig 7.** Effect of EC and DHBA and an inhibitor of NOX (DPI) on ROS generation and levels of p-38. NRK-52E cells were incubated in the presence or absence of 10 µM DPI for 1 h and later with 5 µM EC or 5 µM DHBA for 2 h followed by the HG+LPS challenge (22 h). (A) ROS production was expressed as percent of control are means ± SD of 7-10 different samples per condition. (B) Bands of representative experiments. (C) Percentage data of p-p38/p38 ratios relative to controls (means ± SD, n=7-9). Equal loading of Western blots was ensured by β-actin. Means without a common letter differ significantly (P<0.05).
**Fig 8.** Effect of EC and DHBA and a NOX inhibitor (DPI) on levels of TNF-α, IL-6 and MCP-1.

NRK-52E cells were incubated in the presence or absence of 10 µM DPI for 1 h and later with 5 µM EC or 5 µM DHBA for 2 h followed by the HG+LPS challenge (22 h). (A) Bands of representative experiments. Percentage data of (B) TNF-α, (C) IL-6, and (D) MCP-1 relative to the control condition (means ± SD, n=8-10). Equal loading of Western blots was ensured by β-actin. Means without a common letter differ significantly (P<0.05).

**Fig 9.** Schematic overview showing the analysed targets involved in the EC- and DHBA-induced protective effects in NRK-52E cells. Arrows indicate positive inputs (activation), whereas perpendicular lines show negative inputs (inhibition).
Figure 1

284x219mm (300 x 300 DPI)
Figure 2

284x219mm (300 x 300 DPI)
Figure 3

284x219mm (300 x 300 DPI)
Figure 4

284x219mm (300 x 300 DPI)
Figure 5

284x219mm (300 x 300 DPI)
Figure 6

284x219mm (300 x 300 DPI)
Figure 7

284x219mm (300 x 300 DPI)
Figure 8

284x219mm (300 x 300 DPI)
Figure 9

254x190mm (300 x 300 DPI)
Table 1. Effect of high glucose (HG) and lipopolysaccharide (LPS) treatment on cell viability, ROS generation, and values in culture media of TNF-α and IL-6. NRK-52E cells were treated with the noted concentrations for 24 h. Results for cell viability and ROS are expressed as a percent relative to the control condition, and cytokine levels were measured by ELISA. Values are means ± SD of 6-10 data. Means in a column without a common letter differ, \( P<0.05 \).

<table>
<thead>
<tr>
<th>HG (30 mM)</th>
<th>LPS (μg/mL)</th>
<th>Cell viability (% of control)</th>
<th>ROS (% of control)</th>
<th>TNF-α (pg/mL)</th>
<th>IL-6 (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td></td>
<td>100.30 ± 4.68(^a)</td>
<td>100.13 ± 5.48(^a)</td>
<td>15.18 ± 0.51(^a)</td>
<td>18.15 ± 0.48(^a)</td>
</tr>
<tr>
<td>HG (30 mM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>102.43 ± 3.75(^a)</td>
<td>122.13 ± 8.04(^b)</td>
<td>15.10 ± 0.67(^a)</td>
<td>18.09 ± 0.76(^a)</td>
</tr>
<tr>
<td></td>
<td>0.25</td>
<td>108.94 ± 9.64(^a)</td>
<td>122.38 ± 9.88(^b)</td>
<td>15.38 ± 0.65(^a)</td>
<td>17.87 ± 1.60(^a)</td>
</tr>
<tr>
<td></td>
<td>0.5</td>
<td>107.68 ± 11.17(^a)</td>
<td>127.86 ± 12.52(^b)</td>
<td>17.21 ± 0.42(^b)</td>
<td>18.86 ± 1.91(^a)</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>109.29 ± 10.26(^a)</td>
<td>138.62 ± 5.07(^c)</td>
<td>19.97 ± 0.54(^cd)</td>
<td>24.50 ± 1.38(^b)</td>
</tr>
<tr>
<td></td>
<td>1.5</td>
<td>106.18 ± 9.54(^a)</td>
<td>124.30 ± 4.53(^b)</td>
<td>19.19 ± 0.20(^c)</td>
<td>23.42 ± 1.05(^b)</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>106.21 ± 11.59(^a)</td>
<td>126.87 ± 5.58(^b)</td>
<td>21.04 ± 0.59(^d)</td>
<td>24.31 ± 1.62(^b)</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>100.14 ± 10.21(^a)</td>
<td>118.87 ± 6.24(^b)</td>
<td>20.81 ± 0.63(^d)</td>
<td>24.72 ± 0.73(^b)</td>
</tr>
</tbody>
</table>
Table 2. Direct effect of EC, DHBA, DHPAA and HPPA on values of TNF-α and IL-6 in culture media. NRK-52E cells were treated with the noted concentrations of the mentioned compounds for 24 h. TNF-α and IL-6 were analysed by ELISA. Values are means ± SD of 6-10 data. Means in a column without a common letter differ, $P<0.05$.

<table>
<thead>
<tr>
<th></th>
<th>TNF-α (pg/mL)</th>
<th>IL-6 (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>15.09 ± 0.55$^a$</td>
<td>18.04 ± 1.63$^a$</td>
</tr>
<tr>
<td>EC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 μM</td>
<td>14.62 ± 0.48$^a$</td>
<td>18.76 ± 1.55$^a$</td>
</tr>
<tr>
<td>5 μM</td>
<td>14.96 ± 0.62$^a$</td>
<td>18.33 ± 1.32$^a$</td>
</tr>
<tr>
<td>10 μM</td>
<td>15.00 ± 1.04$^a$</td>
<td>18.08 ± 1.56$^a$</td>
</tr>
<tr>
<td>DHBA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 μM</td>
<td>15.21 ± 0.45$^a$</td>
<td>18.90 ± 1.41$^a$</td>
</tr>
<tr>
<td>5 μM</td>
<td>15.12 ± 0.71$^a$</td>
<td>18.93 ± 0.94$^a$</td>
</tr>
<tr>
<td>10 μM</td>
<td>14.62 ± 0.92$^a$</td>
<td>18.74 ± 1.16$^a$</td>
</tr>
<tr>
<td>DHPAA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 μM</td>
<td>14.97 ± 0.57$^a$</td>
<td>19.50 ± 1.36$^a$</td>
</tr>
<tr>
<td>5 μM</td>
<td>14.86 ± 0.63$^a$</td>
<td>18.92 ± 1.17$^a$</td>
</tr>
<tr>
<td>10 μM</td>
<td>15.20 ± 0.51$^a$</td>
<td>18.35 ± 2.08$^a$</td>
</tr>
<tr>
<td>HPPA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 μM</td>
<td>15.41 ± 0.75$^a$</td>
<td>19.73 ± 1.14$^a$</td>
</tr>
<tr>
<td>5 μM</td>
<td>14.94 ± 0.47$^a$</td>
<td>19.36 ± 1.36$^a$</td>
</tr>
<tr>
<td>10 μM</td>
<td>14.91 ± 0.58$^a$</td>
<td>18.92 ± 0.79$^a$</td>
</tr>
</tbody>
</table>
Table 3. Potential protective effect of EC, DHBA, DHPAA and HPPA on ROS generation and culture media values of TNF-α and IL-6. NRK-52E cells were treated with the noted concentrations of the mentioned compounds for 2 h, and then HG (30 mM) plus LPS (1 µg/mL) were added for 22 h. Results for ROS are expressed as a percent relative to the control condition, and TNF-α and IL-6 were measured by ELISA. Values are means ± SD of 6-10 data. Means in a column without a common letter differ, P<0.05.

<table>
<thead>
<tr>
<th></th>
<th>ROS (% of control)</th>
<th>TNF-α (pg/mL)</th>
<th>IL-6 (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Control</strong></td>
<td>100.00 ± 6.08&lt;sup&gt;a&lt;/sup&gt;</td>
<td>15.09 ± 0.55&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18.05 ± 1.93&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>HG+LPS</strong></td>
<td>130.49 ± 5.65&lt;sup&gt;b&lt;/sup&gt;</td>
<td>20.89 ± 0.54&lt;sup&gt;b&lt;/sup&gt;</td>
<td>25.63 ± 1.90&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>EC+HG+LPS</strong></td>
<td>1 μM 127.56 ± 4.66&lt;sup&gt;b&lt;/sup&gt;</td>
<td>20.64 ± 0.85&lt;sup&gt;bd&lt;/sup&gt;</td>
<td>24.34 ± 1.79&lt;sup&gt;bc&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>5 μM 100.20 ± 8.90&lt;sup&gt;a&lt;/sup&gt;</td>
<td>17.40 ± 0.51&lt;sup&gt;c&lt;/sup&gt;</td>
<td>21.93 ± 1.33&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>10 μM 98.10 ± 5.63&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18.06 ± 0.69&lt;sup&gt;c&lt;/sup&gt;</td>
<td>22.05 ± 1.14&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>DHBA+HG+LPS</strong></td>
<td>1 μM 136.96 ± 8.21&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>21.10 ± 0.52&lt;sup&gt;bd&lt;/sup&gt;</td>
<td>23.89 ± 1.96&lt;sup&gt;bc&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>5 μM 103.20 ± 4.16&lt;sup&gt;a&lt;/sup&gt;</td>
<td>16.81 ± 0.57&lt;sup&gt;c&lt;/sup&gt;</td>
<td>22.22 ± 1.51&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>10 μM 102.20 ± 3.25&lt;sup&gt;a&lt;/sup&gt;</td>
<td>17.14 ± 0.19&lt;sup&gt;c&lt;/sup&gt;</td>
<td>22.28 ± 1.61&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>DHPAA+HG+LPS</strong></td>
<td>1 μM 128.92 ± 9.18&lt;sup&gt;b&lt;/sup&gt;</td>
<td>21.28 ± 0.32&lt;sup&gt;bd&lt;/sup&gt;</td>
<td>30.59 ± 2.05&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>5 μM 134.18 ± 9.15&lt;sup&gt;b&lt;/sup&gt;</td>
<td>23.46 ± 0.94&lt;sup&gt;d&lt;/sup&gt;</td>
<td>29.76 ± 1.93&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>10 μM 133.83 ± 1.87&lt;sup&gt;b&lt;/sup&gt;</td>
<td>23.54 ± 0.25&lt;sup&gt;bd&lt;/sup&gt;</td>
<td>31.73 ± 2.11&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>HPPA+HG+LPS</strong></td>
<td>1 μM 129.17 ± 6.59&lt;sup&gt;b&lt;/sup&gt;</td>
<td>21.19 ± 0.81&lt;sup&gt;bd&lt;/sup&gt;</td>
<td>25.17 ± 1.90&lt;sup&gt;bc&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>5 μM 149.63 ± 2.96&lt;sup&gt;c&lt;/sup&gt;</td>
<td>19.44 ± 0.31&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>26.80 ± 0.50&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>10 μM 139.63 ± 11.58&lt;sup&gt;bc&lt;/sup&gt;</td>
<td>20.81 ± 0.75&lt;sup&gt;bd&lt;/sup&gt;</td>
<td>27.16 ± 1.33&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>
Inflammation
TNF-α, IL-6, MCP-1
MAPKs
ROS, NOX-4

HG + LPS

EC + DHBA

HG + LPS

272x193mm (300 x 300 DPI)